NICE Gives OK To Roche's Rozlytrek
Second Histology-Independent Drug To Win Backing
Patients in England with NTRK fusion-positive solid tumors will now have access to Rozlytrek, the second cancer treatment that can be used to treat tumors regardless of where in the body they originated.
You may also be interested in...
English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.